Nghĩa của từ postmenopausal bằng Tiếng Anh
adjective
following the cessation of menstrual cycle; following middle age
Đặt câu với từ "postmenopausal"
1. Training of support Afferentation in postmenopausal women.
2. Anastrozole is used to treat breast cancer in postmenopausal women
3. Aromatase inhibitors stop the production of estrogen in postmenopausal women
4. * all postmenopausal women below age 65 who have risk factors for osteoporosis ;
5. The Crone was the postmenopausal woman who enjoyed a special, revered status
6. What Anastrozole Is Used For: Anastrozole is used to treat breast cancer in postmenopausal women.
7. * Complications that women may develop in the postmenopausal period include osteoporosis and heart disease .
8. 24 The controls were 713 postmenopausal women aged 45-65 not taking hormone replacements.
9. Arimidex (Anastrozole) is a non-steroidal aromatase inhibitor used to treat breast cancer in postmenopausal women
10. Aromatase inhibitors generally are used for estrogen receptor positive (ER+) breast cancer in postmenopausal women.
11. Anastrozole is a hormone treatment recommended by NICE to prevent breast cancer in high-risk postmenopausal women.
12. Corticosteroids can cause a loss of bone density in men and women, particularly among postmenopausal women
13. Thus, Androidal fat mass, but not isoflavonetreatment, is likely to alter the cardiometabolic profile in healthy postmenopausal women
14. Thus, Androidal fat mass, but not isoflavonetreatment, is likely to alter the cardiometabolic profile in healthy postmenopausal women.
15. Calcitonin-salmon nasal spray has not been shown to increase spinal bone mineral density in early postmenopausal women
16. Other interaction studies in postmenopausal women have demonstrated the absence of any interaction potential with tamoxifen or hormone replacement therapy (oestrogen
17. The prevalence of vulvovaginal Atrophy is about 75% to 90% among postmenopausal women and therefore, all of us are affected
18. Aromatase inhibitors (AIs) are a class of drugs used in the treatment of breast cancer in postmenopausal women and gynecomastia in men
19. Among both pre- and postmenopausal women, the most prevalent sexual problem is chronic low sexual desire, or hypoactive sexual desire disorder (HSDD).
20. Aromatase inhibitors (AIs) are an important component of adjuvant endocrine therapy in postmenopausal women with estrogen receptor (ER)-positive breast cancer
21. Pharmacokinetic interaction studies in postmenopausal women have demonstrated the absence of any interaction potential with tamoxifen or hormone replacement therapy (oestrogen
22. Anastrozole (Arimidex ®) for the adjuvant treatment of postmenopausal women with oestrogen receptor-positive early invasive breast cancer (September 2005) Recommended with restrictions
23. Millions of postmenopausal women are taking a Bisphosphonate like oral alendronate (Fosamax) or intravenous (IV) zoledronic acid (Reclast) to increase bone density
24. The ATAC study involved over 9,000 postmenopausal early breast cancer patients who were treated with tamoxifen (Nolvadex), Anastrozole (Arimidex) or both for five years
25. Aromatase inhibitors are given to postmenopausal breast cancer patients to reduce the level of oestrogen in those whose tumours were fuelled by the hormone .
26. Aromatase inhibitors (AIs), such as Aromasin and Femara are standard, ASCO guideline recommended treatment as adjuvant therapy in early stage breast cancer in postmenopausal women
27. Study population was formed by postmenopausal women. QUS was compared to the dual X-ray absorptiometry (DXA) as the most frequently used method of measurement.
28. Anastrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.
29. Atrophic vaginitis (AV, vaginal atrophy), thinning and inflammation of the vaginal walls secondary to a decline in estrogen, is experienced by almost 50% of postmenopausal women
30. Anastrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.
31. The ovaries are the richest source of Aromatase, although some Aromatase is present in adipose tissue, which is also an important source of estrogen in postmenopausal women
32. It is also indicated for the hormonal treatment of advanced/metastatic breast cancer in women with natural or artificially-induced postmenopausal status, who have disease progression following antiestrogen therapy. Femara* (letrozole) is also indicated for use in the extended adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women who have received approximately 5 years of prior standard adjuvant tamoxifen therapy.
33. The aromatase inhibitors Anastrozole and letrozole are approved to be given to postmenopausal women as initial therapy for metastatic or locally advanced hormone-sensitive breast cancer (12, 13)
34. Miacalcin nasal spray is a Calcitonin, indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable
35. Anastrozole is used to treat breast cancer in postmenopausal women. It is often given to women whose cancer has progressed even after taking tamoxifen (Nolvadex, Soltamox)
36. Calcitonin is a hormone used to treat symptoms of Paget’s disease of the bone, hypercalcemia (high levels of calcium in the blood) and postmenopausal osteoporosis (bone weakening)
37. Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer
38. Urethral Caruncles are benign, distal urethral lesions that are most commonly found in postmenopausal women, although a case of urethral Caruncle has also been described in a male
39. A high consumption of oxidized polyunsaturated fatty acids (PUFAs), which are found in most types of vegetable oil, may increase the likelihood that postmenopausal women will develop breast cancer.
40. Descriptions Calcitonin nasal spray is used together with calcium and vitamin D to treat bone loss in women with postmenopausal osteoporosis who have been postmenopause for at least 5 years
41. Estrogen therapy alone , however , is associated with an increased risk of developing endometrial cancer ( cancer of the lining of the uterus ) in postmenopausal women who have not had their uterus surgically removed .
42. For example , researchers have shown that long-term use of phytoestrogens in postmenopausal women led to an overgrowth of the tissues lining the uterus ( endometrial hyperplasia ) which can be a precursor to cancer .
43. The effects of walking and aerobic dancing on the bones of 73 recently postmenopausal women have been compared by photon absorptiometry of the distal radius with a control group who did not exercise.
44. Anastrozole doses of 1mg or more suppressed mean serum concentrations of estradiol in postmenopausal women with advanced breast cancer to the lower limit of detection (3.7 pmol/L) in multiple daily dosing trials (range, 0.5 mg to 10 mg)
45. Anastrozole is approved to treat: Breast cancer in postmenopausal women who have any of the following types of breast cancer-- Early-stage, hormone receptor–positive (HR+) breast cancer. It is used in women who have already received other treatment.
46. Shoko Shimizu, Yugo Ishino, Takashi Takeda, Masaya Tohyama, Shingo Miyata, " Antidepressive Effects of Kamishoyosan through 5-HT1AReceptor and PKA-CREB-BDNF Signaling in the Hippocampus in Postmenopausal Depression-Model Mice ", Evidence-Based Complementary and Alternative Medicine, vol
47. Findings from randomized controlled trials have shown the Aromatase inhibitors exemestane and anastrozole may lower the risk of developing breast cancer in postmenopausal women at high risk [].However, Aromatase inhibitors are not FDA-approved for use as risk-lowering drugs.
48. We hypothesized that soy isoflavones would attenuate the anticipated increase in Androidal fat mass in postmenopausal women during the 36-month treatment, and thereby favorably modify the circulating cardiometabolic risk factors: triacylglycerol, LDLC, HDL-C, glucose, insulin, uric acid, C-reactive protein, fibrinogen, and homocysteine
49. In the 2nd half of the cycle, during pregnancy, during antiovulatory treatment and in postmenopausal period, the endosalpingeal epithelium of pars of uterina, isthmus, ampulla and infundibulum is characterized by proliferative quiescence (i.e. lack of mitoses, a small quantity of nuclei, a simple epithelium).
50. We hypothesized that soy isoflavones would attenuate the anticipated increase in Androidal fat mass in postmenopausal women during the 36-month treatment, and thereby favorably modify the circulating cardiometabolic risk factors: triacylglycerol, LDL-C, HDL-C, glucose, insulin, uric acid, C-reactive protein, fibrinogen, and homocysteine